May 07, 2025

FDA Approves Low-Dose Chlorthalidone Tablet

The FDA has approved HemiClor, a 12.5-mg chlorthalidone tablet, providing patients with a low-dose option.

Conexiant

May 07, 2025

Electric Pulse Procedure May Improve T2D

A minimally invasive procedure using electrical pulses in the small intestine shows promise in significantly improving type 2 diabetes, with benefits rivaling gastric bypass surgery.

Reuters

May 01, 2025

Phthalates Linked to Cardiovascular Mortality Globally

Researchers linked di-2-ethylhexylphthalate plastic exposure to over 350,000 cardiovascular deaths and 10 million years of life lost, supporting calls for international regulatory measures.

Conexiant

May 01, 2025

Semaglutide Shows Potential in Liver Disease Trial

Phase 3 trial finds weekly semaglutide 2.4mg significantly improved liver histology in patients with MASH and moderate to advanced fibrosis.

Conexiant

April 30, 2025

ApoB Count and Lp(a) Levels Key to CAD Risk

Total apoB particle count and Lp(a) levels best reflect coronary artery disease risk, with researchers noting that lipid-related atherosclerotic risk is most accurately reflected by the total count of apoB-P.

Conexiant

April 29, 2025

Can Five Proteins Predict Liver Disease?

"Imagine if we could predict risk of metabolic dysfunction-associated steatotic liver disease (MASLD) years before it starts."

Conexiant

April 29, 2025

Surgical Management of Foreign Body Ingestion in Adults: Case Series

Diagnosis relies heavily on a careful history, including the nature of the ingested material, and complementary imaging studies.

Conexiant

April 28, 2025

Higher Heart Risk Seen in Inflammatory Arthritis With IFG

Prediabetes in inflammatory arthritis patients raised cardiovascular risk by over twofold, researchers reported in a population-based cohort study.

Conexiant

April 28, 2025

Oral Semaglutide Cuts Cardiovascular Event Risk

Oral semaglutide was superior to placebo in reducing the risk of major adverse cardiovascular events, researchers reported in the SOUL trial involving over 9,600 adults with high-risk type 2 diabetes.

Conexiant